Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 5, Pages 317–325
http://dx.doi.org/10.1155/2013/935943
Research Article

Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma

Department of Cellular & Molecular Biology, Beijing TB and Thoracic Tumor Research Institution/Beijing Chest Hospital, Capital Medical University, 97 Beimachang, Tongzhou, Beijing 101149, China

Received 15 June 2013; Revised 20 August 2013; Accepted 21 August 2013

Academic Editor: Sun-Il Hwang

Copyright © 2013 Li Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. C. Tiwari, T. Murray et al., “Cancer statistics, 2004,” CA: A Cancer Journal for Clinicians, vol. 54, no. 1, pp. 8–29, 2004. View at Google Scholar · View at Scopus
  2. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar
  6. C. J. Sherr, “Cancer cell cycles,” Science, vol. 274, no. 5293, pp. 1672–1677, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Satyanarayana and P. Kaldis, “Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms,” Oncogene, vol. 28, no. 33, pp. 2925–2939, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Santamaria and S. Ortega, “Cyclins and CDKS in development and cancer: lessons from genetically modified mice,” Frontiers in Bioscience, vol. 11, no. 1, pp. 1164–1188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Galderisi, F. P. Jori, and A. Giordano, “Cell cycle regulation and neural differentiation,” Oncogene, vol. 22, no. 33, pp. 5208–5219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Jin, F. D. Smith, C. Stark et al., “Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization,” Current Biology, vol. 14, no. 16, pp. 1436–1450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Yue, X. Zhao, L. Zhang et al., “Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis,” Clinical Lung Cancer, vol. 12, no. 1, pp. 43–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Xu, Z. Wang, J. Wang, J. Li, H. Wang, and W. Yue, “Lentivirus-mediated knockdown of cyclin Y (CCNY) inhibits glioma cell proliferation,” Oncology Research, vol. 18, no. 8, pp. 359–364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Zhong, S. P. Coe, A. J. Stromberg, N. H. Khattar, J. R. Jett, and E. A. Hirschowitz, “Profiling tumor-associated antibodies for early detection of non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 1, no. 6, pp. 513–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Y. Zhang, C. A. Casiano, X. X. Peng, J. A. Koziol, E. K. L. Chan, and E. M. Tan, “Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 2, pp. 136–143, 2003. View at Google Scholar · View at Scopus
  15. S. J. Storr, J. Chakrabarti, A. Barnes, A. Murray, C. J. Chapman, and J. F. R. Robertson, “Use of autoantibodies in breast cancer screening and diagnosis,” Expert Review of Anticancer Therapy, vol. 6, no. 8, pp. 1215–1223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Covini, E. K. L. Chan, M. Nishioka, S. A. Morshed, S. I. Reed, and E. M. Tan, “Immune response to cyclin B1 in hepatocellular carcinoma,” Hepatology, vol. 25, no. 1, pp. 75–80, 1997. View at Google Scholar · View at Scopus
  17. H. Suzuki, D. F. Graziano, J. McKolanis, and O. J. Finn, “T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease,” Clinical Cancer Research, vol. 11, no. 4, pp. 1521–1526, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Koziol, J. Y. Zhang, C. A. Casiano et al., “Recursive partitioning as an approach to selection of immune markers for tumor diagnosis,” Clinical Cancer Research, vol. 9, no. 14, pp. 5120–5126, 2003. View at Google Scholar · View at Scopus
  19. H. Lu, V. Goodell, and M. L. Disis, “Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer,” Journal of Proteome Research, vol. 7, no. 4, pp. 1388–1394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Y. Zhang, “Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis,” Cancer Detection and Prevention, vol. 28, no. 2, pp. 114–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. F. D. Shi, J. Y. Zhang, D. Liu et al., “Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens,” Prostate, vol. 63, no. 3, pp. 252–258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. W. T. Yue, X. T. Zhao, L. N. Zhang et al., “Overexpression of cyclin Y in non-small cell lung cancer is associated with cancer cell proliferation,” Science China Life Sciences, vol. 53, no. 4, pp. 511–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Y. Zhang, R. Megliorino, X. X. Peng, E. M. Tan, Y. Chen, and E. K. L. Chan, “Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma,” Journal of Hepatology, vol. 46, no. 1, pp. 107–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Li, L. J. Wang, X. Ying et al., “Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer,” Scandinavian Journal of Immunology, vol. 75, no. 3, pp. 342–349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Fernández Madrid, “Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis,” Cancer Letters, vol. 230, no. 2, pp. 187–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Li, A. Karjalainen, H. Koskinen et al., “p53 autoantibodies predict subsequent development of cancer,” International Journal of Cancer, vol. 114, no. 1, pp. 157–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Wang, J. Yu, A. Sreekumar et al., “Autoantibody signatures in prostate cancer,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1224–1235, 2005. View at Publisher · View at Google Scholar · View at Scopus